Why did Moderna flu-COVID vaccine stay shelved in US?

Europe authorized first; US application was withdrawn

A combined mRNA vaccine targeting both flu and COVID-19 has received authorization in Europe before it moves forward in the United States. The reporting indicates that Moderna’s European authorization arrived first, while the US pathway stalled.

The immediate reason given is policy and application status: Moderna withdrew its FDA application last year. As a result, even though the vaccine was developed in the U.S., it remains “shelved” in the US according to the available story text.

Why this matters

• Timing differences affect preparedness: If Europe moves ahead with approvals, rollout and real-world evidence gathering can begin earlier there.
• Regulatory decisions shape market availability: Even for products that perform well in trials, authorization timing can determine who gets access first.
• Public confidence depends on consistency: Separate regulatory tracks can cause confusion among clinicians and patients, especially for vaccines with overlapping respiratory disease targets.

What’s not specified

The excerpt does not explain whether the FDA delay was due to manufacturing, clinical data, safety concerns, or business strategy; it only states that the application was withdrawn. It also doesn’t provide the authorization country list, dosing details, or trial outcomes in the text shown.

Overall, the key takeaway for readers is that European authorization has advanced while the US process has not, primarily because the FDA application was removed from consideration.